Why the study?
Does 99mTc-Sestamibi SPECT accurately detect myocardial viability compared to NH3/FDG PET in patients with ischemic cardiomyopathy?
Population
50 patients with ischemic cardiomyopathy, mean age 57+/-7 years, ejection fraction 28 +/- 8%.
Comparison
99mTc-Sestamibi Single Photon Emission… vs Positron Emission Tomography with 13N-ammonia…
Design
Cross-sectional, Patients underwent SPECT and PET imaging in random order
Authors
Loading...
SPECT may offer a practical alternative to PET for viability assessment in ischemic cardiomyopathy; leaves open need for prospective outcome validation.
Does 99mTc-Sestamibi SPECT accurately detect myocardial viability compared to NH3/FDG PET in patients with ischemic cardiomyopathy?
99mTc-Sestamibi SPECT provides an acceptable, more readily available alternative to NH3/FDG PET for delineating myocardial viability in patients with severe ischemic cardiomyopathy.
Anne Kaltoft, Morten Bøttcher, Niels Pet (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: